Bovine adiponectin,ADP ELISA Kit
- Known as:
- Bovine adiponectin,ADP Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- YHB0006BO
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- yehua
- Gene target:
- Bovine adiponectin ADP ELISA Kit
Related genes to: Bovine adiponectin,ADP ELISA Kit
- Gene:
- ADIPOQ NIH gene
- Name:
- adiponectin, C1Q and collagen domain containing
- Previous symbol:
- ACDC
- Synonyms:
- ACRP30, AdipoQ, apM1, GBP28, adiponectin
- Chromosome:
- 3q27.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-26
- Date modifiied:
- 2016-10-05
Related products to: Bovine adiponectin,ADP ELISA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: Bovine adiponectin,ADP ELISA Kit
- Type 2 diabetes mellitus (T2DM) and autoimmune thyroid disease (AITD) are complex disorders involving metabolic, immune, and hormonal dysregulation. Adipocytokines from adipose tissue influence metabolism, inflammation, and immune regulation. We investigated adiponectin, resistin, and visfatin in relation to thyroid, glucose, and metabolic parameters in adults with T2DM, AITD, both conditions, and healthy controls. A total of 385 adults were recruited. Clinical, anthropometric, and laboratory parameters were assessed, including glycemia, glycated hemoglobin (HbA1c), free thyroxine (fT4), thyroid-stimulating hormone (TSH), thyroid antibodies, and serum levels of adiponectin, resistin, and visfatin. Correlation and regression analyses were performed, including models adjusted for age, sex, and BMI. Adiponectin was higher in AITD than T2DM (p=0.012), resistin was higher in T2DM&AITD than controls (p=0.004), and visfatin was lower in T2DM than other groups (p<0.001). In T2DM&AITD, adiponectin correlated positively with age and fT4 and negatively with BMI (p=0.028, p=0.034). Resistin correlated inversely with TSH in AITD (p=0.033). Visfatin correlated inversely with thyroid volume in T2DM (p=0.003) and with waist circumference in AITD and T2DM&AITD (p=0.007, p=0.020). After adjustment, resistin remained higher in T2DM&AITD vs. controls (p=0.013) and visfatin and adiponectin remained lower in T2DM vs. controls (p=0.049 and p=0.045, respectively). This study highlights distinct adipocytokine profiles in individuals with metabolic and autoimmune thyroid conditions. Adiponectin, resistin, and visfatin may be potential biomarkers for disease severity and metabolic dysfunction. Further research is needed to elucidate the mechanistic pathways linking adipocytokines to the pathophysiology of T2DM and AITD. Key words Type 2 diabetes mellitus " Autoimmune thyroid disease " Adipocytokines " Metabolic dysfunction. - Source: PubMed
Jochmanová ISchröner ZSotak ŠFelšöci MarekPetrášová DMitníková MBertková IWagnerová HLazúrová I - The perithyroidal adipose tissue (PAT), given its direct anatomical proximity to the thyroid gland, has long been postulated as a modulator of the thyroid tumor microenvironment. However, its cellular composition, functional heterogeneity, and specific roles in thyroid cancer progression remain unknown. To address these knowledge gap, we performed single-nucleus RNA sequencing of PAT from patients with papillary thyroid carcinoma (PTC) and multinodular goiter (MNG), combined with machine learning, proteomics, immunofluorescence, ex vivo assays, and human serum analysis. We constructed the first high-resolution atlas of human PAT, revealing an immune-rich niche and previously unrecognized adipocyte heterogeneity, including thermogenic subpopulations (BL-Ad1, BL-Ad2, OXPHOS-Ad) from distinct progenitors. Functionally, the PAT secretome from PTC substantially enhanced thyroid cancer cell proliferation compared to MNG. Integrated analyses identified a pathogenic adipokine triad characterized by loss of ADIPOQ and gain of NAMPT and IGF1. Restoring ADIPOQ signaling or inhibiting NAMPT/IGF1 suppressed tumor growth in vitro and in vivo. Additionally, we identified CCL14, down-regulated in PTC-derived OXPHOS-Ad, as a key immune regulator. Reduced CCL14-CCR1 signaling impaired CD80 expression in M1-like macrophages, disrupting CD80-CD28 costimulation and consequently diminishing T cell proliferation and recruitment. Consistently, circulating CCL14 levels were reduced in PTC patients. In conclusion, PAT acts as a dynamic endocrine and immunomodulatory component of the tumor microenvironment that promotes thyroid tumor growth through adipokine-mediated and immune-dependent mechanisms. - Source: PubMed
Publication date: 2026/07/14
Long QiaoyunZhang ZhaoxiLin BoYu ZhehanXu MingxiZhao Shi-TingLi JieGu PingXie MengyuanZhao XuemeiDeng TuoYang WeiqinCheng Alfred SYang WahLv WeimingPan YongqinHui Hannah Xiaoyan - Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder, which is commonly related to reduced insulin responsiveness and altered appetite-related hormones. In this study, we have evaluated how combined metformin and sulfonylurea therapy affects glycemic indicators and appetite hormones, with special focus on hormone ratios. Sixty participants were involved in the study: 30 diabetic patients receiving combined metformin-sulfonylurea therapy and 30 conditionally healthy individuals serving as controls. Fasting blood samples were collected to assess indicators of glycemic control, lipid profiles, and hormone levels using standard biochemical assays and ELISA. The patient group showed clear increases in fasting glucose, HbA1c, insulin, insulin resistance indices, lipid profile measurements, and leptin levels, whereas the levels of HDL, ghrelin, and adiponectin were markedly decreased compared with the control group (p < 0.001). The results of the study show that T2DM patients continue to have both insulin resistance and poor blood glucose control despite combined metformin-sulfonylurea therapy. Alterations in appetite hormones also reflect underlying metabolic dysregulation, and hormonal ratios, especially the leptin/adiponectin ratio, are more accurate indicators of this imbalance than individual hormone measurements. - Source: PubMed
Hussein S MZaidan N K - Follistatin (FST) binds to and neutralizes members of the transforming growth factor-beta (TGF-β) superfamily, thereby regulating diverse physiological processes, including regulation of skeletal muscle, adipose, and bone homeostasis. FST also promotes adipose browning and enhances energy metabolism, leading to improved plasma lipid profiles and metabolic health in mice. Given the emerging association between brown adipose tissue (BAT) activation and reduced atherosclerosis, we investigated the anti-atherogenic potential of FST. Transcriptomic and metabolomic analyses of the Hybrid Mouse Diversity Panel (HMDP) revealed that expression was negatively correlated with aortic lesion area and positively correlated with the expression of multiple adipose browning-associated genes. Adeno-associated viral delivery of Fst (AAV1-FST344) in mice significantly reduced aortic lesion area, improved plasma lipid profiles, and decreased expression of adhesion (VCAM1) and inflammatory (iNOS, TNF-α) markers in white adipose tissue (WAT), liver, and heart. gene delivery also markedly increased uncoupling protein 1 (UCP1) expression in WAT, consistent with WAT browning. Integrated correlation analyses of expression with tissue metabolites, together with plasma metabolite-lesion associations identified in the HMDP, implicated the arginase 1 (Arg1)-mediated metabolic pathway as a key regulator of atherogenesis. Consistent with these findings, Arg1 expression was significantly elevated in WAT, liver, and heart of AAV1-FST344-treated mice and in wild-type versus -knockout mouse embryonic fibroblasts (MEFs). Immunostaining localized Arg1 predominantly to CD68 macrophages in heart and liver. Given recent evidence identifying Arg1 as a novel mediator of efferocytosis, these findings suggest that Arg1 may promote macrophage metabolic reprogramming and resolution of inflammation by enhancing the clearance of apoptotic cells. Furthermore, gene delivery increased the expression of fibroblast growth factor 21 () and adiponectin (AdipoQ) in WAT. Collectively, these findings identify as a novel anti-atherogenic regulator that protects against vascular disease by promoting adipose browning, improving lipid metabolism, and activating Arg1-mediated metabolic pathways. - Source: PubMed
Publication date: 2026/07/02
Dirakvand GolnazPervin ShehlaVilla BrianLe ChristyYohanna KristineGrijalva VictorChattopadhyay ArnabSinha Satyesh KReddy Srinivasa TSingh Rajan - Neurodegenerative diseases (NDDs) exhibit considerable molecular heterogeneity, making it difficult to pinpoint robust, disease-specific biomarkers. Although proteomic studies have deepened our understanding of individual disorders, systematic cross-disease comparisons with cross-platform validation remain scarce, especially for rare conditions like spinal and bulbar muscular atrophy (SBMA). To address this gap, we conducted a comparative plasma proteomic analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 264 participants across major neurodegenerative and related diagnostic groups, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), SBMA, and cognitively healthy controls. This unified framework allowed us to capture both disease-specific and shared protein signatures across neurodegenerative conditions. Candidate proteins were then validated in the UK Biobank (Olink Explore) and the Global Neurodegeneration Proteomics Consortium (SomaScan). Of 23 proteins assessed in the UK Biobank, four unique proteins (yielding six disease-protein associations) showed nominally significant and directionally concordant changes; of 20 proteins represented by 27 probes tested in the Global Neurodegeneration Proteomics Consortium, seven proteins reached nominal significance, all with full directional concordance across both cohorts. Notably, IGFBP2 was consistently elevated in AD and PD across independent datasets, pointing to shared metabolic dysregulation, while ADIPOQ showed parallel increases in the same conditions, reinforcing convergent shifts in energy metabolism. By contrast, CRTAC1 and COMP were selectively reduced in motor neuron diseases, suggesting disease-enriched alterations in extracellular matrix composition. Taken together, our findings provide a cross-disease, cross-platform framework for uncovering reproducible proteomic biomarkers and shed light on both overlapping and distinct molecular pathways in neurodegeneration. - Source: PubMed
Publication date: 2026/07/10
Choi YoungtaeLee ShinryeAshim JanbolatYu WookyungCho EunjiLee Ho-WonPark Jin-SungYoon Jong HyukKim Hyung-JunCheon Mookyung